Factors such as Medicaid coverage, income levels, age, and healthcare infrastructure play a crucial role in determining who can currently benefit from these medications, and addressing these disparities will be key to maximizing access to GLP-1 therapies in the years ahead
Shashank Upadhye, a founding partner of Upadhye Tang LLP an IP & FDA boutique law firm in Chicago and author of Generic Pharmaceutical Patent & FDA Law, a textbook now in its 14th edition, served as chief in-house counsel at three leading pharmaceutical companies: Apotex, Inc., Sandoz-Novartis, and Eon Labs, Inc
Peptide injections for weight loss are typically aimed at adults with: A BMI of 27+ with a weight-related health issue, or a BMI over 30 Little success with previous diet/exercise attempts No medullary thyroid cancer or MEN 2 familial history No current pregnancy or pregnancy plans For tailored insights into your eligibility for weight loss peptides, reach out to Klinic in Palo Alto
Counterfeit weight loss drugs have serious health risks, according to the pharmaceutical companies and federal officials
There is no single best approach
I collaborated with the Noom team to design and roll out Nooms first-ever offering of oral medicationMetforminas part of its mission to provide accessible weight-loss solutions